Item 8.01. Other Events.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), with which Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) collaborates in the development and
commercialization of RELISTOR, has informed Progenics that global net sales of
RELISTOR for the current year through the first quarter of 2009 were $1.9
million. RELISTOR sales are growing from a modest base as Wyeth works to build
awareness of its utility in addressing opioid-induced constipation in palliative
care and pursues opportunities to expand its use into additional patient
settings. New educational and promotional programs are ongoing, including
focused regional initiatives implemented with physicians, caregivers and nurses.
To date, RELISTOR has been launched in 19 markets including the U.S., Canada, 14
European Union member states, Australia, Venezuela and Chile. Launches are
planned for 2009 in 13 additional markets, including Spain, Italy, France,
Argentina and Brazil, the largest individual markets after the U.S.
